Catalyst Pharmaceuticals, Inc: Julian Baker And Felix Baker’s Baker Bros. Advisors Lp Disclosed Stake

February 14, 2018 - By Michael Collier

 Catalyst Pharmaceuticals, Inc: Julian Baker And Felix Baker's Baker Bros. Advisors Lp Disclosed Stake

Investors sentiment decreased to 2 in 2017 Q3. Its down 0.22, from 2.22 in 2017Q2. It fall, as 3 investors sold Catalyst Pharmaceuticals, Inc. shares while 15 reduced holdings. 17 funds opened positions while 19 raised stakes. 34.72 million shares or 4.30% more from 33.29 million shares in 2017Q2 were reported.

Fincl Bank Of America De holds 0% or 7,132 shares. Geode Capital Management Ltd Co has 0% invested in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX). Balyasny Asset Mgmt Lc holds 0% or 14,800 shares in its portfolio. Nationwide Fund holds 0% or 40,137 shares. Bnp Paribas Arbitrage Sa has invested 0% of its portfolio in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX). Moreover, Schwab Charles Invest Mngmt has 0% invested in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX). Wells Fargo & Mn stated it has 29,128 shares or 0% of all its holdings. Morgan Stanley has invested 0% in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX). First Allied Advisory Serv Inc accumulated 0% or 26,000 shares. Malaga Cove Capital Ltd Llc, a California-based fund reported 20,000 shares. Alliancebernstein L P holds 0% in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) or 11,800 shares. Northern Tru stated it has 811,513 shares. Blackrock holds 3.72M shares. Legal General Public Ltd Co has 0% invested in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) for 10,602 shares. California State Teachers Retirement stated it has 0% of its portfolio in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX).

The New Julian Baker And Felix Baker’s Baker Bros. Advisors Lp Holding in Catalyst Pharmaceuticals, Inc

Baker Bros. Advisors Lp reported SC 13G/A form with the SEC for Catalyst Pharmaceuticals, Inc. Access it here: 000114420418007914. As reported by Julian Baker And Felix Baker’s Baker Bros. Advisors Lp, the filler owns 667% or 5,852,153 shares of the Health Care–company.

Catalyst Pharmaceuticals, Inc stake is new for [reportingPerson]. Date of activity: December 31, 2017. This shows Julian Baker And Felix Baker’s Baker Bros. Advisors Lp’s positive view for Catalyst Pharmaceuticals, Inc. For a hedge fund managing $8.20 billion in assets and having 25+ experts this is interesting position.

The hedge fund is investor in the Health Care sector. In the manager’s last 13-F, we saw 12% of Julian Baker And Felix Baker’s Baker Bros. Advisors Lp’s portfolio is in the sector.

Catalyst Pharmaceuticals, Inc Institutional Sentiment

Filings show 89 investors own Catalyst Pharmaceuticals, Inc. The ownership in Q3 2015 is high, at Infinity of the outstanding shares. This is increased by 5659252. 49229682 were owned by these investors. 15 funds opened new Catalyst Pharmaceuticals, Inc stakes, 28 increased positions. There were 11 that closed positions and 27 reduced them.

Arthur B Cohen And Joseph Healey Healthcor Management Lp is an investor bullish on Catalyst Pharmaceuticals, Inc, owning 385500 shares as of Q3 2015 for 0.07% of its portfolio. Julian Baker And Felix Baker Baker Bros Advisors Lp owns 7335692 shares or 0.20% of its portfolio. NY Tanaka Capital Management Inc have 0.85% of its portfolio for 111693 shares. Further, Broadfin Capital Llc reported stake worth 0.70% of its portfolio. The NY Consonance Capital Management Lp owns 5802885 shares. Catalyst Pharmaceuticals, Inc is 2.45% of its portfolio.

Business Profile

Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company’s Firdapse is indicated for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). Firdapse consists of the phosphate salt of amifampridine. The Company has completed the Phase III trial of Firdapse. The Company’s CPP-109 (vigabatrin) is a gamma-aminobutyric acid (GABA) aminotransferase inhibitor. CPP-109 is indicated for the treatment of Tourette’s Disorder. The Company’s CPP-115 is a GABA aminotransferase inhibitor. CPP-115 is indicated for the treatment of selected neurological indications, such as complex partial seizures and Tourette’s Disorder, and epilepsy.

SEC Form 13G.

Analysts await Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) to report earnings on March, 21. They expect $-0.06 EPS, down 20.00 % or $0.01 from last year’s $-0.05 per share. After $-0.05 actual EPS reported by Catalyst Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 20.00 % negative EPS growth.

The stock increased 1.19% or $0.04 during the last trading session, reaching $3.41. About 292,218 shares traded. Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) has risen 267.48% since February 14, 2017 and is uptrending. It has outperformed by 250.78% the S&P500.

Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies for people with rare debilitating diseases. The company has market cap of $349.44 million. The Company’s lead product candidate is Firdapse, a proprietary form of amifampridine phosphate, which is in second Phase III clinical trials for the treatment of patients with Lambert-Eaton Myasthenic syndrome; and is in small blinded clinical trial to treat Congenital Myasthenic syndromes, as well as is in Phase II/III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis. It currently has negative earnings. The firm also develops CPP-115, a gamma-aminobutyric acid aminotransferase inhibitor that is in Phase Ib clinical trial for the treatment of epilepsy, infantile spams, and Tourette's disorder; and CPP-109 to treat Tourette's disorder.

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Ratings Coverage

Among 5 analysts covering Catalyst Pharmaceuticals (NASDAQ:CPRX), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Catalyst Pharmaceuticals has $8.0 highest and $4 lowest target. $5.75’s average target is 68.62% above currents $3.41 stock price. Catalyst Pharmaceuticals had 13 analyst reports since April 26, 2016 according to SRatingsIntel. Piper Jaffray maintained the stock with “Buy” rating in Friday, December 1 report. Roth Capital maintained Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) rating on Wednesday, August 30. Roth Capital has “Buy” rating and $4.75 target. The firm earned “Neutral” rating on Tuesday, April 26 by Piper Jaffray. The rating was upgraded by PiperJaffray on Wednesday, October 5 to “Overweight”. As per Tuesday, October 31, the company rating was maintained by SunTrust. Roth Capital maintained Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) on Wednesday, November 1 with “Buy” rating. As per Monday, November 27, the company rating was maintained by SunTrust. H.C. Wainwright maintained it with “Buy” rating and $600 target in Friday, August 11 report. The rating was maintained by Piper Jaffray with “Buy” on Monday, August 7. As per Thursday, August 10, the company rating was maintained by Roth Capital.

Another recent and important Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) news was published by Globenewswire.com which published an article titled: “Catalyst Pharmaceuticals Announces Plans to Resubmit New Drug Application for …” on February 12, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: